Bayer is trading 4.17% down at €48.68, with no clear company-specific catalyst identified for the September 29 decline.
- A Reuters report published September 28 described a favorable court decision for Bayer’s Monsanto unit in its mRNA patent litigation, but did not link the news to the current price move.
- Available German market coverage shows the DAX slightly higher, so broader market movement does not clearly explain the decline.